Ionization-specific prediction of blood-brain permeability.
暂无分享,去创建一个
Remigijus Didziapetris | Kiril Lanevskij | Pranas Japertas | R. Didziapetris | Alanas Petrauskas | K. Lanevskij | P. Japertas | A. Petrauskas
[1] V. Hruby,et al. Improved bioavailability to the brain of glycosylated Met-enkephalin analogs , 2000, Brain Research.
[2] Y. Sugiyama,et al. Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. , 1996, The Journal of pharmacology and experimental therapeutics.
[3] T. Tsuruo,et al. Contribution of P‐glycoprotein to efflux of ramosetron, a 5‐HT3 receptor antagonist, across the blood‐brain barrier , 2002, The Journal of pharmacy and pharmacology.
[4] C. L. Graff,et al. Variable modulation of opioid brain uptake by P-glycoprotein in mice. , 2004, Biochemical pharmacology.
[5] Buchwald,et al. Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. , 1999, Advanced drug delivery reviews.
[6] Q. Smith,et al. Characterization of the blood–brain barrier choline transporter using the in situ rat brain perfusion technique , 2001, Journal of neurochemistry.
[7] Irene Luque Ruiz,et al. QSAR models based on isomorphic and nonisomorphic data fusion for predicting the blood brain barrier permeability , 2007, J. Comput. Chem..
[8] Christophe Rousselle,et al. Development of an In Situ Mouse Brain Perfusion Model and its Application to mdr1a P-Glycoprotein-Deficient Mice , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[9] S. Yamada,et al. Quantitative evaluation of brain distribution and blood-brain barrier efflux transport of probenecid in rats by microdialysis: possible involvement of the monocarboxylic acid transport system. , 1997, The Journal of pharmacology and experimental therapeutics.
[10] R. Spector. Transport of amantadine and rimantadine through the blood-brain barrier. , 1988, The Journal of pharmacology and experimental therapeutics.
[11] N. Kawai,et al. Glutamine transport at the blood–brain and blood–cerebrospinal fluid barriers , 2003, Neurochemistry International.
[12] Gary M. Pollack,et al. Effect of mdr1a P-Glycoprotein Gene Disruption, Gender, and Substrate Concentration on Brain Uptake of Selected Compounds , 2001, Pharmaceutical Research.
[13] T. Terasaki,et al. Involvement of organic anion transporters in the efflux of uremic toxins across the blood–brain barrier , 2006, Journal of neurochemistry.
[14] W. Oldendorf,et al. Transient blood-brain barrier passage of polar compounds at low pH. , 1994, American Journal of Physiology.
[15] D. E. Clark,et al. In Silico Predictions of Blood-Brain Barrier Penetration: Considerations to “Keep in Mind” , 2005, Journal of Pharmacology and Experimental Therapeutics.
[16] A. Leo,et al. Substituent constants for correlation analysis in chemistry and biology , 1979 .
[17] N. Abbott. Prediction of blood-brain barrier permeation in drug discovery from in vivo, in vitro and in silico models. , 2004, Drug discovery today. Technologies.
[18] Harpreet S. Chadha,et al. Molecular Factors Influencing Drug Transfer across the Blood‐Brain Barrier , 1997, The Journal of pharmacy and pharmacology.
[19] M. Abraham. Application of solvation equations to chemical and biochemical processes , 1993 .
[20] Remigijus Didziapetris,et al. Fragmental Methods in the Design of New Compounds. Applications of The Advanced Algorithm Builder , 2002 .
[21] Yanfeng Wang,et al. The Simultaneous Estimation of the Influx and Efflux Blood-Brain Barrier Permeabilities of Gabapentin Using a Microdialysis-Pharmacokinetic Approach , 1996, Pharmaceutical Research.
[22] Prabha Garg,et al. In Silico Prediction of Blood Brain Barrier Permeability: An Artificial Neural Network Model , 2006, J. Chem. Inf. Model..
[23] Andreas Klamt,et al. Prediction of Blood-Βrain Partitioning and Human Serum Albumin Binding Based on COSMO-RS σ-Moments , 2007, J. Chem. Inf. Model..
[24] P. Riederer,et al. The flavone hispidulin, a benzodiazepine receptor ligand with positive allosteric properties, traverses the blood–brain barrier and exhibits anticonvulsive effects , 2004, British journal of pharmacology.
[25] Bahram Hemmateenejad,et al. Accurate prediction of the blood–brain partitioning of a large set of solutes using ab initio calculations and genetic neural network modeling , 2006, J. Comput. Chem..
[26] Y. Sawada,et al. Comparison of blood-brain barrier permeability in mice and rats using in situ brain perfusion technique. , 2000, American journal of physiology. Heart and circulatory physiology.
[27] F. Tse,et al. Brain uptake of dihydroergotamine after intravenous and nasal administration in the rat , 1998, Biopharmaceutics & drug disposition.
[28] Alexandre Varnek,et al. Correlation of blood-brain penetration using structural descriptors. , 2006, Bioorganic & medicinal chemistry.
[29] D. Mock,et al. Biotin Transport Through the Blood‐Brain Barrier , 1987, Journal of Neurochemistry.
[30] S. Yamada,et al. Brain distribution of 6-mercaptopurine is regulated by the efflux transport system in the blood-brain barrier. , 2000, Life sciences.
[31] Alex Avdeef,et al. Absorption and drug development , 2003 .
[32] P. Selzer,et al. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. , 2000, Journal of medicinal chemistry.
[33] R. Himes,et al. Chemical modification of paclitaxel (Taxol) reduces P-glycoprotein interactions and increases permeation across the blood-brain barrier in vitro and in situ. , 2005, Journal of medicinal chemistry.
[34] A. Leo,et al. Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design. , 1987, Journal of pharmaceutical sciences.
[35] Ramamurthi Narayanan,et al. In silico ADME modelling: prediction models for blood-brain barrier permeation using a systematic variable selection method. , 2005, Bioorganic & medicinal chemistry.
[36] T. Kaneko,et al. Permeability of brain structures and other peripheral tissues to prostaglandins D2, E2 and F2 alpha in rats. , 1992, The Journal of pharmacology and experimental therapeutics.
[37] Mark L. Lewis,et al. Predicting Penetration Across the Blood-Brain Barrier from Simple Descriptors and Fragmentation Schemes , 2007, J. Chem. Inf. Model..
[38] P D Leeson,et al. Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonists. , 1997, Journal of medicinal chemistry.
[39] W H Oldendorf,et al. Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. , 1971, The American journal of physiology.
[40] Meihua Tu,et al. Development of a computational approach to predict blood-brain barrier permeability. , 2004, Drug metabolism and disposition: the biological fate of chemicals.
[41] C. Rousselle,et al. Screening of Multidrug-Resistance Sensitive Drugs by In Situ Brain Perfusion in P-Glycoprotein-Deficient Mice , 2001, Pharmaceutical Research.
[42] J. Viña,et al. Structure of the blood-brain barrier and its role in the transport of amino acids. , 2006, The Journal of nutrition.
[43] K. Boje,et al. Blood–brain barrier transport studies of organic guanidino cations using an in situ brain perfusion technique , 2000, Brain Research.
[44] W. Hass,et al. Unsymmetrical alkyl aryl thiourea compounds for use as cerebral blood flow tracers. , 1980, The American journal of physiology.
[45] W. Pardridge. The blood-brain barrier: Bottleneck in brain drug development , 2005, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.
[46] M. Abraham,et al. The use of characteristic volumes to measure cavity terms in reversed phase liquid chromatography , 1987 .
[47] Juan M. Luco,et al. QSAR Studies on Blood-Brain Barrier Permeation , 2006 .
[48] T. Terasaki,et al. Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier. , 1993, The Journal of pharmacology and experimental therapeutics.
[49] H Kubinyi,et al. Quantitative structure--activity relationships. 7. The bilinear model, a new model for nonlinear dependence of biological activity on hydrophobic character. , 1977, Journal of medicinal chemistry.
[50] S. Cisternino,et al. Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P‐glycoprotein at the blood–brain barrier in mice and rats , 2003, British journal of pharmacology.
[51] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .
[52] Q. Smith,et al. Brain Uptake of Nonsteroidal Anti-Inflammatory Drugs: Ibuprofen, Flurbiprofen, and Indomethacin , 2006, Pharmaceutical Research.
[53] R. Spector,et al. Transport of diphenhydramine in the central nervous system. , 1987, The Journal of pharmacology and experimental therapeutics.
[54] S. Rapoport,et al. An in situ brain perfusion technique to study cerebrovascular transport in the rat. , 1984, The American journal of physiology.
[55] W. Geldenhuys,et al. Cation Transport Specificity at the Blood–Brain Barrier , 2004, Neurochemical Research.
[56] R. Lipnick. Outliers: their origin and use in the classification of molecular mechanisms of toxicity. , 1991, The Science of the total environment.
[57] V A Levin,et al. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. , 1980, Journal of medicinal chemistry.
[58] Michael H Abraham,et al. The factors that influence permeation across the blood-brain barrier. , 2004, European journal of medicinal chemistry.
[59] Y. Sugiyama,et al. Distributed model analysis of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine distribution in brain tissue and cerebrospinal fluid. , 1997, The Journal of pharmacology and experimental therapeutics.
[60] I. Tamai,et al. Efflux transport of a new quinolone antibacterial agent, HSR-903, across the blood-brain barrier. , 1999, The Journal of pharmacology and experimental therapeutics.
[61] G R Wilkinson,et al. Brain uptake of benzodiazepines: effects of lipophilicity and plasma protein binding. , 1988, The Journal of pharmacology and experimental therapeutics.
[62] R. Spector. Fatty Acid Transport Through the Blood‐Brain Barrier , 1988, Journal of neurochemistry.
[63] K. Hosoya,et al. The blood-brain barrier efflux transporters as a detoxifying system for the brain. , 1999, Advanced drug delivery reviews.
[64] M. Hanano,et al. Investigation of transport mechanism of pentazocine across the blood-brain barrier using the in situ rat brain perfusion technique. , 2002, Journal of pharmaceutical sciences.
[65] J. Bourre,et al. Taurine transport at the blood-brain barrier: an in vivo brain perfusion study , 1995, Brain Research.
[66] S. Curry,et al. Brain uptake and biotransformation of remacemide hydrochloride, a novel anticonvulsant. , 1994, Drug metabolism and disposition: the biological fate of chemicals.
[67] Phil Jeffrey,et al. Central Nervous System Drug Disposition: The Relationship between in Situ Brain Permeability and Brain Free Fraction , 2007, Journal of Pharmacology and Experimental Therapeutics.
[68] U. Bickel,et al. How to measure drug transport across the blood-brain barrier , 2011, NeuroRX.
[69] E. Hansson,et al. Astrocyte–endothelial interactions at the blood–brain barrier , 2006, Nature Reviews Neuroscience.
[70] W. Pardridge,et al. Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier. , 1990, The Journal of pharmacology and experimental therapeutics.
[71] C. Rousselle,et al. Apparent Lack of Mrp1-Mediated Efflux at the Luminal Side of Mouse Blood-Brain Barrier Endothelial Cells , 2003, Pharmaceutical Research.